445 related articles for article (PubMed ID: 15843620)
1. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease.
Van Raamsdonk JM; Pearson J; Slow EJ; Hossain SM; Leavitt BR; Hayden MR
J Neurosci; 2005 Apr; 25(16):4169-80. PubMed ID: 15843620
[TBL] [Abstract][Full Text] [Related]
2. In Vivo MRI Evidence that Neuropathology is Attenuated by Cognitive Enrichment in the Yac128 Huntington's Disease Mouse Model.
Steventon JJ; Harrison DJ; Trueman RC; Rosser AE; Jones DK; Brooks SP
J Huntingtons Dis; 2015; 4(2):149-60. PubMed ID: 26397896
[TBL] [Abstract][Full Text] [Related]
3. Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington's disease.
Abada YS; Schreiber R; Ellenbroek B
Behav Brain Res; 2013 Feb; 238():243-51. PubMed ID: 23123142
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal analysis of the behavioural phenotype in YAC128 (C57BL/6J) Huntington's disease transgenic mice.
Brooks S; Higgs G; Janghra N; Jones L; Dunnett SB
Brain Res Bull; 2012 Jun; 88(2-3):113-20. PubMed ID: 20460143
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analyses of operant performance on the serial implicit learning task (SILT) in the YAC128 Huntington's disease mouse line.
Brooks SP; Jones L; Dunnett SB
Brain Res Bull; 2012 Jun; 88(2-3):130-6. PubMed ID: 21763407
[TBL] [Abstract][Full Text] [Related]
6. YAC128 mouse model of Huntington disease is protected against subtle chronic manganese (Mn)-induced behavioral and neuropathological changes.
Wilcox JM; Pfalzer AC; Tienda AA; Debbiche IF; Cox EC; Totten MS; Erikson KM; Harrison FE; Bowman AB
Neurotoxicology; 2021 Dec; 87():94-105. PubMed ID: 34543681
[TBL] [Abstract][Full Text] [Related]
7. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Rogers DA; Lu G; Barakauskas VE; Barr AM; Honer WG; Hayden MR; Leavitt BR
Exp Neurol; 2005 Dec; 196(2):266-72. PubMed ID: 16129433
[TBL] [Abstract][Full Text] [Related]
8. Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice.
McGregor AL; D'Souza G; Kim D; Tingle MD
Neuropharmacology; 2017 Apr; 116():233-246. PubMed ID: 28025093
[TBL] [Abstract][Full Text] [Related]
9. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Rogers DA; Bissada N; Vogl AW; Hayden MR; Leavitt BR
Hum Mol Genet; 2005 May; 14(10):1379-92. PubMed ID: 15829505
[TBL] [Abstract][Full Text] [Related]
10. Treadmill exercise delays the onset of non-motor behaviors and striatal pathology in the CAG
Stefanko DP; Shah VD; Yamasaki WK; Petzinger GM; Jakowec MW
Neurobiol Dis; 2017 Sep; 105():15-32. PubMed ID: 28502806
[TBL] [Abstract][Full Text] [Related]
11. YAC128 Huntington's disease transgenic mice show enhanced short-term hippocampal synaptic plasticity early in the course of the disease.
Ghilan M; Bostrom CA; Hryciw BN; Simpson JM; Christie BR; Gil-Mohapel J
Brain Res; 2014 Sep; 1581():117-28. PubMed ID: 24949563
[TBL] [Abstract][Full Text] [Related]
12. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.
Park KHJ; Franciosi S; Parrant K; Lu G; Leavitt BR
Neuroscience; 2017 Jun; 352():79-87. PubMed ID: 28391013
[TBL] [Abstract][Full Text] [Related]
13. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
Wood NI; Glynn D; Morton AJ
Neurobiol Dis; 2011 Jun; 42(3):427-37. PubMed ID: 21324361
[TBL] [Abstract][Full Text] [Related]
14. Age-dependent alterations in the cortical entrainment of subthalamic nucleus neurons in the YAC128 mouse model of Huntington's disease.
Callahan JW; Abercrombie ED
Neurobiol Dis; 2015 Jun; 78():88-99. PubMed ID: 25772440
[TBL] [Abstract][Full Text] [Related]
15. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
16. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model.
Harrison DJ; Busse M; Openshaw R; Rosser AE; Dunnett SB; Brooks SP
Exp Neurol; 2013 Oct; 248():457-69. PubMed ID: 23911978
[TBL] [Abstract][Full Text] [Related]
17. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation.
Carter RJ; Lione LA; Humby T; Mangiarini L; Mahal A; Bates GP; Dunnett SB; Morton AJ
J Neurosci; 1999 Apr; 19(8):3248-57. PubMed ID: 10191337
[TBL] [Abstract][Full Text] [Related]
18. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice.
Mazarakis NK; Cybulska-Klosowicz A; Grote H; Pang T; Van Dellen A; Kossut M; Blakemore C; Hannan AJ
J Neurosci; 2005 Mar; 25(12):3059-66. PubMed ID: 15788762
[TBL] [Abstract][Full Text] [Related]
19. Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model.
Kim D; Jeon J; Cheong E; Kim DJ; Ryu H; Seo H; Kim YK
Mol Neurobiol; 2016 May; 53(4):2276-86. PubMed ID: 25976370
[TBL] [Abstract][Full Text] [Related]
20. Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease.
Lawhorn C; Smith DM; Brown LL
Neurobiol Dis; 2008 Dec; 32(3):471-8. PubMed ID: 18809498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
